⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
19,945
Total Claims
$8.7M
Drug Cost
1,382
Beneficiaries
$6,288
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 18,720 Cardiology providers
+312%
Cost per patient vs peers
$6,288 vs $1,524 avg
+114%
Brand preference vs peers
29.3% vs 13.7% avg
Brand vs Generic
71% generic
Brand: 5,802 claims · $8.2M
Generic: 14,032 claims · $458K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 943 | $1.3M |
| Empagliflozin | 820 | $1.2M |
| Rivaroxaban | 910 | $1.2M |
| Dapagliflozin Propanediol | 464 | $623K |
| Apixaban | 456 | $606K |
| Tafamidis | 13 | $460K |
| Sacubitril/Valsartan | 306 | $441K |
| Dulaglutide | 253 | $378K |
| Tirzepatide | 215 | $302K |
| Finerenone | 112 | $163K |
| Evolocumab | 134 | $131K |
| Sitagliptin Phosphate | 72 | $107K |
| Canagliflozin | 67 | $97K |
| Ezetimibe | 1,858 | $79K |
| Dronedarone Hcl | 37 | $73K |
Prescribing Profile
Patient Profile
73
Avg Age
51%
Female
1.65
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About